Global Basal Cell Skin Cancer Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Basal Cell Skin Cancer Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Basal cell carcinoma (BCC) is the most common form of skin cancer and the most frequently occurring form of all cancers. BCCs arise from abnormal, uncontrolled growth of basal cells. Because BCCs grow slowly, most are curable and cause minimal damage when caught and treated early.

Market Overview:

The latest research study on the global Basal Cell Skin Cancer Treatment market finds that the global Basal Cell Skin Cancer Treatment market reached a value of USD 1145.8 million in 2022. It’s expected that the market will achieve USD 2072.4 million by 2028, exhibiting a CAGR of 10.38% during the forecast period.

Market Challenges

COVID-19 brings challenges to Basal Cell Skin Cancer Treatment. COVID-19 has greatly influenced the daily life and medical system all over the world. On March 11th, 2020, the coronavirus outbreak was declared a global pandemic by the World Health Organization. Then, most countries imposed an almost complete blockade in an effort to limit the spread of diseases among their populations and effectively support the national health system. At this stage, governments of various countries also restricted visits to medical and health care facilities, delayed treatment that was usually considered unnecessary, and prevented patients from seeking care.
COVID-19 pandemic fundamentally changed the daily work of clinic and surgery, and had a great impact on all aspects of medical care and surgery practice, including labor force, program priority and the risk of viral diseases and intraoperative transmission. This has also had a great impact on cancer care. Because some patients missed proper screening and diagnosis, the treatment was interrupted. There are also some high-risk patients with skin cancer who have delayed their appointments for fear of infection, which may indicate the peak of Basal Cell Skin Cancer Treatment in the future.
With regard to basal cell carcinoma, NCCN suggested that the treatment should be delayed for at least three months during the outbreak of pandemic, because its soft tissue is minimally invasive and has little metastatic capacity. This treatment delay may lead to an increase in tumor size without oncological influence.

The increase of basal cell carcinoma

Basal cell carcinoma is most common type of non-melanoma skin cancer and generally referred to as a ‘rodent ulcers’. Skin has three main types of cells in the top layer of the skin in which basal cells line the epidermis layers. Basal cells are shed or replaced as new ones grow/form. Basal cell carcinoma developed when DNA damages from exposure to UV radiation from the sun due to this tanning trigger the changes in basal cells of the outer most layers of epidermis and uncontrolled cell growth. The carcinoma looks like open sores, red patches, shiny bumps, slightly elevated growth on skin with rolled edges.
Basal cell carcinoma affects slightly more men than women. It occurs more often in older people. People with fair skin and light eyes are more likely to get BCC. It is 19 times more common in whites than blacks, but people of color may still be affected. People who have had BCC once are at higher risk for developing another lesion.
Basic cell carcinoma is usually easy to detect and has an excellent record of successful treatment, although it may recur in some cases. Early diagnosis and treatment can reduce the risk of recurrence and metastasis. Global basal cell carcinoma and the increase of the elderly are important factors to promote the growth of this market.

Market Restraints

Lack of patient awareness may hinder the global basal cell cancer treatment market. Basal cell carcinoma is the malignant tumor with the highest incidence of skin cancer, which is easy to occur in middle-aged and elderly people. 70%~90% of basal cell cancers occur in forehead, cheeks and nose, etc. Cancer cells grow slowly, showing local invasion and destruction, and rarely metastasize. At first, the nodules with small wax-like luster are gradually enlarged, and an ulcer is formed in the middle, which is ignored by people because it is painless.
In addition, misdiagnosis and missed diagnosis are also one of the main factors that hinder the development of the market. BCC is usually localized skin cancer. It is important to make a correct diagnosis, because misdiagnosing one skin cancer as another may lead to the wrong treatment or delay the effective treatment. Missed BCC (false negative result) will lead to the spread or even disfigurement of cancer cells. If you are diagnosed with skin cancer without cancer (i.e. false positive result), it may bring unnecessary biopsy or treatment, and may bring pain and anxiety to the patient.

Region Overview:

Geographically, North America held the largest market share – 37.29% in 2022.

Company Overview:

Roche is one of the major players operating in the Basal Cell Skin Cancer Treatment market, holding a share of 26.81% in 2023.

Roche

Roche is a global leader in pharmaceutical and diagnostic fields, and is committed to improving human life by promoting scientific progress. Combining the unique advantages of pharmaceutical and diagnostic businesses, Roche Group has become the leader of individualized medical treatment, providing the most targeted treatment plan for every patient through individualized medical treatment.

Viatris

Formed in November 2020, Viatris bring together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories.

Segmentation Overview:

Among different product types, Topical Treatment segment is anticipated to contribute the largest market share in 2028.

Topical Treatment

Prescription creams or ointments might be considered for treating small and thin basal cell carcinomas when surgery isn't an option.

Hedgehog Pathway Inhibitor Therapy

A Hedgehog pathway inhibitor (HHI) can be used to treat patients with locally advanced BCC who are not candidates for surgery or radiation therapy, or whose disease has recurred after surgery or radiation therapy, and those with metastatic BCC.

Application Overview:

In the Basal Cell Skin Cancer Treatment market, 57.12% of the total value was generated through the Hospitals segment by application in 2022.

Key Companies in the global Basal Cell Skin Cancer Treatment market covered in Chapter 3:

Bausch Health Companies
Sun Pharmaceuticals
Viatris
Roche
Taro Pharmaceuticals
Perrigo Company plc

In Chapter 4 and Chapter 14.2, on the basis of types, the Basal Cell Skin Cancer Treatment market from 2018 to 2029 is primarily split into:

Topical Treatment
Hedgehog Pathway Inhibitor Therapy
Other

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Basal Cell Skin Cancer Treatment market from 2018 to 2029 covers:

Hospitals
Specialty Clinics
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)